Skip to Content

Adjuvant nivolumab improves disease-free survival in patients with muscle invasive bladder cancer

Treatment with the PD1 inhibitor nivolumab with or without cisplatin-based chemotherapy after radical surgery significantly improve disease-free survival in patients with muscle-invasive urothelial cancer, regardless of PD-L1 status.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top